Subscribe
shutterstock_521453077_rolandmagnusson
Roland Magnusson / Shutterstock.com
2 April 2019Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

Biopharmaceutical company  AstraZeneca has entered into an agreement with Japanese pharmaceutical company  Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

More on this story

Americas
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12 February 2020   American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.
Big Pharma
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14 November 2019   Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB